RU2019125436A - Новый подход к иммунотерапии, нацеленной на vegfr-2 - Google Patents
Новый подход к иммунотерапии, нацеленной на vegfr-2 Download PDFInfo
- Publication number
- RU2019125436A RU2019125436A RU2019125436A RU2019125436A RU2019125436A RU 2019125436 A RU2019125436 A RU 2019125436A RU 2019125436 A RU2019125436 A RU 2019125436A RU 2019125436 A RU2019125436 A RU 2019125436A RU 2019125436 A RU2019125436 A RU 2019125436A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- protein
- cancer
- sequence
- amino acid
- Prior art date
Links
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 title claims 7
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 title claims 7
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 title claims 7
- 238000009169 immunotherapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims 19
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 241000607142 Salmonella Species 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 230000002238 attenuated effect Effects 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108091008605 VEGF receptors Proteins 0.000 claims 12
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 12
- 108091008048 CMVpp65 Proteins 0.000 claims 8
- 108020004414 DNA Proteins 0.000 claims 8
- 102000053602 DNA Human genes 0.000 claims 8
- 238000002619 cancer immunotherapy Methods 0.000 claims 8
- 238000011275 oncology therapy Methods 0.000 claims 8
- 108010041986 DNA Vaccines Proteins 0.000 claims 6
- 229940021995 DNA vaccine Drugs 0.000 claims 6
- 238000002512 chemotherapy Methods 0.000 claims 6
- 238000001959 radiotherapy Methods 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims 4
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 claims 4
- 102000003735 Mesothelin Human genes 0.000 claims 4
- 108090000015 Mesothelin Proteins 0.000 claims 4
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims 4
- 101710127857 Wilms tumor protein Proteins 0.000 claims 4
- 102100022748 Wilms tumor protein Human genes 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 241001138501 Salmonella enterica Species 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 230000001332 colony forming effect Effects 0.000 claims 2
- 108010072257 fibroblast activation protein alpha Proteins 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 229930027917 kanamycin Natural products 0.000 claims 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 2
- 229960000318 kanamycin Drugs 0.000 claims 2
- 229930182823 kanamycin A Natural products 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4225—Growth factors
- A61K40/423—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001135—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17156718.3 | 2017-02-17 | ||
| EP17156718 | 2017-02-17 | ||
| PCT/EP2018/053918 WO2018149982A1 (en) | 2017-02-17 | 2018-02-16 | Novel vegfr-2 targeting immunotherapy approach |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019125436A true RU2019125436A (ru) | 2021-03-17 |
Family
ID=58094260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019125436A RU2019125436A (ru) | 2017-02-17 | 2018-02-16 | Новый подход к иммунотерапии, нацеленной на vegfr-2 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10980868B2 (enExample) |
| EP (1) | EP3583200A1 (enExample) |
| JP (2) | JP7712060B2 (enExample) |
| KR (2) | KR20190117603A (enExample) |
| CN (1) | CN110291187A (enExample) |
| AU (1) | AU2018222777B9 (enExample) |
| BR (1) | BR112019016925A2 (enExample) |
| CA (1) | CA3050833A1 (enExample) |
| IL (1) | IL268186A (enExample) |
| MX (1) | MX2019009724A (enExample) |
| RU (1) | RU2019125436A (enExample) |
| SG (1) | SG11201907391SA (enExample) |
| WO (1) | WO2018149982A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3310379T3 (pl) * | 2015-06-18 | 2020-03-31 | Vaximm Ag | Szczepionka dna wycelowana w vegfr-2 do terapii skojarzonej |
| CA3109430A1 (en) * | 2018-09-05 | 2020-03-12 | Vaximm Ag | Neoantigen targeting dna vaccine for combination therapy |
| CN113527509B (zh) * | 2020-04-17 | 2023-09-26 | 深圳华大生命科学研究院 | 含有重组蛋白和保护蛋白的复合物在治疗肺鳞癌中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO337687B1 (no) | 2011-07-08 | 2016-06-06 | Norsk Elektro Optikk As | Hyperspektralt kamera og metode for å ta opp hyperspektrale data |
| US9493738B2 (en) * | 2011-12-22 | 2016-11-15 | Vaximm Ag | Method for producing high yield attenuated Salmonella strains |
| EP3603664A1 (en) | 2012-07-05 | 2020-02-05 | Vaximm AG | Dna vaccine for use in pancreatic cancer patients |
| ES2675020T3 (es) * | 2013-04-25 | 2018-07-05 | Vaximm Ag | Vectores basados en Salmonella para inmunoterapia del cáncer dirigida al gen WT1 del tumor de Wilms |
| SG11201604911VA (en) * | 2013-12-18 | 2016-07-28 | Vaximm Gmbh | Novel msln targeting dna vaccine for cancer immunotherapy |
| WO2015142875A1 (en) * | 2014-03-17 | 2015-09-24 | The Trustees Of The University Of Pennsylvania | Compositions and methods using modified salmonella |
| PL3310379T3 (pl) | 2015-06-18 | 2020-03-31 | Vaximm Ag | Szczepionka dna wycelowana w vegfr-2 do terapii skojarzonej |
| BR112019000657A2 (pt) | 2016-07-13 | 2019-04-24 | Vaximm Ag | método para produzir uma vacina de dna para imunoterapia de câncer e vacina de dna |
-
2018
- 2018-02-16 JP JP2019544614A patent/JP7712060B2/ja active Active
- 2018-02-16 MX MX2019009724A patent/MX2019009724A/es unknown
- 2018-02-16 EP EP18704568.7A patent/EP3583200A1/en active Pending
- 2018-02-16 US US16/486,425 patent/US10980868B2/en active Active
- 2018-02-16 CN CN201880012318.8A patent/CN110291187A/zh active Pending
- 2018-02-16 KR KR1020197026398A patent/KR20190117603A/ko not_active Ceased
- 2018-02-16 BR BR112019016925-3A patent/BR112019016925A2/pt not_active Application Discontinuation
- 2018-02-16 AU AU2018222777A patent/AU2018222777B9/en active Active
- 2018-02-16 WO PCT/EP2018/053918 patent/WO2018149982A1/en not_active Ceased
- 2018-02-16 RU RU2019125436A patent/RU2019125436A/ru not_active Application Discontinuation
- 2018-02-16 KR KR1020247035606A patent/KR20240170928A/ko active Pending
- 2018-02-16 CA CA3050833A patent/CA3050833A1/en active Pending
- 2018-02-16 SG SG11201907391SA patent/SG11201907391SA/en unknown
-
2019
- 2019-07-21 IL IL268186A patent/IL268186A/en unknown
-
2023
- 2023-08-18 JP JP2023133276A patent/JP2023160838A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023160838A (ja) | 2023-11-02 |
| BR112019016925A2 (pt) | 2020-05-26 |
| KR20190117603A (ko) | 2019-10-16 |
| CN110291187A (zh) | 2019-09-27 |
| US20200038496A1 (en) | 2020-02-06 |
| EP3583200A1 (en) | 2019-12-25 |
| JP2020507332A (ja) | 2020-03-12 |
| AU2018222777B2 (en) | 2024-02-01 |
| JP7712060B2 (ja) | 2025-07-23 |
| IL268186A (en) | 2019-09-26 |
| AU2018222777B9 (en) | 2024-02-22 |
| US10980868B2 (en) | 2021-04-20 |
| WO2018149982A1 (en) | 2018-08-23 |
| SG11201907391SA (en) | 2019-09-27 |
| KR20240170928A (ko) | 2024-12-05 |
| CA3050833A1 (en) | 2018-08-23 |
| MX2019009724A (es) | 2019-10-07 |
| AU2018222777A1 (en) | 2019-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bridle et al. | Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus | |
| RU2019132253A (ru) | Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака | |
| Pol et al. | Maraba virus as a potent oncolytic vaccine vector | |
| RU2016129044A (ru) | Новая вакцина днк, нацеленная на мезотелин, для иммунотерапии рака | |
| JP2020511139A5 (enExample) | ||
| Bridle et al. | Potentiating cancer immunotherapy using an oncolytic virus | |
| Lemay et al. | Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine | |
| De Haan et al. | Viral gene delivery vectors: the next generation medicines for immune-related diseases | |
| Bridle et al. | Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines | |
| RU2015103758A (ru) | Днк-вакцина для применения у пациентов с раком поджелудочной железы | |
| Fan et al. | Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity | |
| JP2011500718A5 (enExample) | ||
| ES2741147T3 (es) | Composición de vacuna | |
| Chen et al. | Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma | |
| JP2019523008A5 (enExample) | ||
| Leslie et al. | Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis | |
| JP2015506704A5 (enExample) | ||
| JP2018535668A5 (enExample) | ||
| JP2017507918A (ja) | Ｈｐｖおよび関連する疾病のための免疫増強治療ワクチン | |
| RU2019125436A (ru) | Новый подход к иммунотерапии, нацеленной на vegfr-2 | |
| Zhao et al. | Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response | |
| JP2018517419A5 (enExample) | ||
| Hirvinen et al. | Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| JP2015506179A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20210217 |